DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Peter Welford - 1 Welford - 1 AstraZeneca's - 1 Jefferies - 1 AstraZeneca's eplontersen - 1 transthyretin - 1 deruxtecan - 1 Pascal Soriot's - 1
Top related locs:
Japan's Daiichi
Top related orgs:
AstraZeneca - 2 Jefferies - 1 AstraZeneca's - 1 Japan's - 1 pharma - 1 Ionis Pharmaceuticals - 1 Citi - 1 donidalorsen - 1

Search resuls for: "eplontersen"


2 mentions found


☆ Jefferies upgrades this pharma stock, citing overlooked 'blockbuster' drug opportunities
  + stars: | 2023-09-25 | by ( Pia Singh | ) www.cnbc.com   time to read: +2 min
AstraZeneca's tozorakimab drug for chronic obstructive pulmonary disease also seems underappreciated, with a potential to reach $4.5 billion in peak sales, according to Jefferies. The firm also suggests up to $3.5 billion in sales for AstraZeneca's eplontersen , a drug aimed at treating hereditary transthyretin-mediated amyloid polyneuropathy. The pharmaceutical giant is also poised to be the frontrunner in breast cancer treatments. Another one of AstraZeneca's breast cancer therapies, also being developed with Daiichi Sankyo, came out with positive news Friday. Its experimental precision drug datopotamab deruxtecan demonstrated an improvement in slowing the progression of a common type of breast cancer in a late-stage trial.
Persons: Peter Welford, Welford, AstraZeneca's, Jefferies, AstraZeneca's eplontersen, transthyretin, deruxtecan, Pascal Soriot's, — CNBC's Michael Bloom Organizations: AstraZeneca, Jefferies, AstraZeneca's, Japan's, pharma Locations: Japan's Daiichi
☆ This little-known pharma stock can rally 50%, Citi says
  + stars: | 2023-07-31 | by ( Brian Evans | ) www.cnbc.com   time to read: +1 min
It's time to buy shares of Ionis Pharmaceuticals , according to Citi. The firm upgraded the stock on Monday to buy from neutral and raised its price target to $60 from $36. "Though HAE is a competitive market, Phase II data hints that it could have an attractive product profile and be a meaningful player," Lebowitz said. Given current valuation, we view the risk-reward on Ionis shares as being skewed positive." Lebowitz also highlighted donidalorsen's phase 2 test performance, which underpinned the stock upgrade.
Persons: David Lebowitz, eplontersen, HAE, Lebowitz, donidalorsen, Ionis, Michael Bloom Organizations: Ionis Pharmaceuticals, Citi, AstraZeneca, donidalorsen, Ionis
0 next >>
Total: 2